Ipsen CEO says UK will likely fall behind post-Brexit

In an interview with UK press, French drugmaker Ipsen (Euronext: IPN) chief executive David Meek has said that that the UK will likely fall behind other major economies in terms of access to medicines, post-Brexit.

Mr Meek told PharmaPhorum he believed that, should marketing authorization in the UK be provided through a separate process, governed by the UK’s Medicines and Healthcare Regulatory Agency (MHRA), the country would be deprioritized by drugmakers.

Describing his firm’s current regulatory approach, he noted that Ipsen currently priorities “the FDA and the EMA,” followed by “the next markets, for example the PMDA in Japan.”